Krilogy Financial LLC Sells 1,571 Shares of Medpace Holdings, Inc. $MEDP

Krilogy Financial LLC decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 39.6% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,398 shares of the company’s stock after selling 1,571 shares during the period. Krilogy Financial LLC’s holdings in Medpace were worth $1,237,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Optiver Holding B.V. bought a new position in Medpace during the third quarter worth $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace in the fourth quarter valued at $30,000. Elyxium Wealth LLC bought a new stake in Medpace in the fourth quarter valued at $30,000. Quarry LP bought a new stake in Medpace in the third quarter valued at $35,000. Finally, Bayban acquired a new position in shares of Medpace during the fourth quarter valued at about $44,000. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.4%

Shares of Medpace stock opened at $519.96 on Friday. The stock has a fifty day simple moving average of $451.02 and a 200 day simple moving average of $496.81. Medpace Holdings, Inc. has a 12-month low of $305.69 and a 12-month high of $628.92. The company has a market capitalization of $14.85 billion, a P/E ratio of 32.68, a price-to-earnings-growth ratio of 2.60 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same period in the prior year, the firm posted $3.67 EPS. Medpace’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Barclays cut their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Robert W. Baird dropped their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Royal Bank Of Canada cut their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, BMO Capital Markets decreased their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $467.08.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.